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the treatment of asthma were not accepted due to comments about population 
and model input, lack of statistical calculations and size of the incremental effects. 
Ranibizumab’s results for age-related macular degeneration were not accepted 
because of a wrong comparator, lack of long term data, assumptions on risks and 
mortality, and uncertainties around health care costs and ICER sensitivity. Finally, 
ZiNL considered the appropriate use of alglucosidase alfa for Pompe’s disease 
to be unsubstantiated because of the population choice for the ICER calculation 
and the use of a higher dose than the registered dose which was not supported 
by scientific data. The outcome results of alglucosidase alfa for cost-effectiveness 
were accepted, however. ConClusions: Although at T= 0 ZiNL provided feedback 
regarding the design of the outcome research study, most of ZiNL’s comments were 
on the final methodology used. The outcome research studies were considered 
to be of mixed quality and the results could often not substantiate the claim of 
cost-effectiveness and appropriate use.
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objeCtives: In the UK, when a technology is recommended by the National 
Institute for Health and Care Excellence (NICE), the NHS is mandated to provide 
the funding to accommodate it within three months. Explicit in NICE’s approach 
to health technology assessment (HTA) is the assumption that the approval of a 
new, cost-increasing technology will result in the displacement of an existing, less 
cost-effective health care programme from elsewhere in the NHS. The objective 
of this study is to identify the actual opportunity costs of specific NICE decisions 
by documenting how in practice local commissioners in Wales accommodated 
financial shocks arising from technology appraisals (TAs). Methods: Interviews 
were conducted with Finance and Medical Directors from all seven Local Health 
Boards (LHBs) in NHS Wales. These interviews covered prioritisation processes, as 
well as methods of financing NICE TAs and other financial “shocks” at each LHB. 
We then undertook a systematic identification of themes and topics from the 
information recorded. Results: The financial impact of NICE TAs is generally 
planned for in advance and the majority of LHBs have contingency funds avail-
able for this purpose. Efficiency savings (defined as reductions in costs with no 
assumed reductions in quality) were a major source of funds for all cost pressures. 
Service displacements were not linkable to particular TAs and there appears to be 
a general lack of explicit prioritisation activities. The Welsh Government has, on 
occasion, acted as the funder of last resort. ConClusions: The assumption that 
newly recommended technologies will displace existing NHS services does not 
appear to hold true in practice. As the additional cost pressures represented by 
new NICE TAs are likely to be accommodated by greater efficiency and increased 
expenditure, the true opportunity cost of HTA decisions is extremely difficult to 
quantify and may even lie outside the NHS.
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objeCtives: Western countries health care systems face growing challenges deal-
ing with disability and death due to chronic diseases. Coordination of health care 
services has become unavoidable. Our objective was to identify the Integrated 
Health Services (IHS) in the major health care markets and understand the fund-
ing process. Methods: IHS provided in Europe, North America and Asia were 
identified through a literature review. Future perspectives were based on country 
policy and observed trends. Results: All studied countries developed IHS such 
as disease management, case management and telemonitoring services, with the 
United States (US) being the major market. However, levels of implementation, 
funding processes and stakeholders involved vary highly between different coun-
tries. Funding processes such as fee for services and capitation are widely used in 
all studied countries and Payment for performance (P4P), bundled payment and 
diagnosis-related group (DRG) for outpatient are in progress, used mainly in the 
US, and to a much lower extent in the United Kingdom (UK) and Germany. Multiple 
IHS exists in France, though inappropriate incentives hinder their development. In 
the US, under the Affordable Care Act, Accountable Care Organisations (ACOs) are 
testing a range of payment models (capitation, one-sided/two-sided shared sav-
ing fee-for-service, bundled/episode payments and P4P). ConClusions: IHS have 
become ubiquitous in all health organisations. All countries studied are expected to 
develop more IHS based on P4P schemes. The P4P of ACOs represents the ultimate 
gold mine for the development of paid health care services. Even if this concept is 
still in progress it will be leading this market. This will also change dramatically the 
way pharmaceutical companies will do business. Drugs will have to be integrated 
in a more complex selling process driven by medium to long term outcome impact. 
The management of confounding factors on outcomes is critical and represents 
the challenge for ACOs.
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objeCtives: The comprehensive implementation of telemedical applications still 
lags behind expectations in Germany. One of the main barriers to innovation is a 
lack of both a willingness to adapt and user’s acceptance. Processes of adoption 
and acceptance are characterized by a network of different factors which influ-
ence attitude and behavior which differ in severity depending on each user group. 
One key factor for accepting and adopting an innovation is the economic frame-
work. We therefore examined the influence of economic factors influencing the 
Senegal, Egypt, Morocco, Algeria and Tunisia) are contributing # 80% of the pharma 
market in Africa. Despite maintaining regional offices within Africa, many major 
Pharma and device manufacturers frequently overlook the continent when sponsor-
ing clinical studies. Cultural barriers, political upheaval and uneven infrastructure 
are certainly causes for the lack of interest. But Africa offers tremendous expertise 
and opportunity for drug and device companies looking for cost-effective study 
sites and appropriate patient drug market populations. Currently more than 45% 
of the whole continent’s clinical trials are being conducted in South Africa and 
hence the need for the next generation clinical trial destination for a drug and 
device manufacturers. These companies can also consider technology transfer by 
partnering with local drug manufacturers and research centers to diversify their 
business portfolio. ConClusions: Africa presents real opportunities that should 
encourage many pharmaceutical companies to really engage in innovative clinical 
research programs in a win-win approach.
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objeCtives: Although, whether biologically active supplements (BAS) are medi-
cines or not is still debatable, BAS keep making their way to the customer basically 
through pharmacies. A worldwide tendency toward “greener” choices when pur-
chasing health status modifiers (HSM) is well documented. Current endeavor studies 
the pharmaceutical market situation (PMS) in Armenia (2009 to 2013) in regard to 
growth trends both in US dollars turnover (USDT) and number of packs sold (NPS) of 
BAS versus medicines, stratified by five leading diseases (LD). Methods: Statistical 
data on morbidity and mortality from the MOH RA were used to identify the leading 
five disease groups in newly identified cases. Further, statistical data on pharmaceu-
tical market from “Pharmexpert” Marketing Research Centre (analysis of wholesale 
sales volumes to the retail drug stores) were investigated to identify growth rate 
(GR) trends of interest. Results: A PMS analysis has shown 11.92% and 6.65% of 
GR (medicines and BAS combined) in USDT and NPS respectively. For medicines 
alone the results were: 11.56% and 6.23% GR in USDT and NPS respectively. As for 
BAS, USDT and NPS, the figures were 21.48% and 15.36% of GR respectively. A further 
stratification by five LM has shown the highest GR in medicines used for treatment 
of Uro-Genital diseases (13.24% and 10.01% for USDT and NPS respectively), whereas 
in BAS the highest GR was in the Cardio-Vascular group (63.84% and 92.82% for USDT 
and NPS respectively). ConClusions: The results of the study go in line with the 
worldwide trends in shifting whenever possible, from medicines to using HSM of 
natural origin, of which BAS are a major part. The study does not claim to identify 
the underlying compound factors influencing such a tendency. However, the reality 
at had compels for studying the levels of BAS administration and use literacy among 
both HSM prescribers and consumers.
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objeCtives: This study seeks to evaluate the incremental benefit scores granted 
to new medicines under the 2011 AMNOG reform in Germany, and if there is a 
correlation between that score and the extent of price reduction after negotiation 
with the statutory health insurance fund. Methods: Resolutions issued by the 
G-BA related to all drugs which achieved the early benefit assessment process 
between January 2011 and June 2014 were reviewed to determine whether the 
drugs were deemed to bring an added benefit. Under AMNOG, an added therapeu-
tic benefit score is granted to medicines according to 6 categories (major, consid-
erable, minor, non-quantifiable, no or less added benefit versus the comparator). 
As part of the study, IHS created an overall quantitative innovation score for each 
product, based on any and all qualitative ratings granted by the G-BA in each 
patient subgroup. The score ranged from 0 (no added benefit proven) to 4 (major 
added benefit) and was weighted against each patient population. An average price 
reduction per innovation score range was then calculated. Results: Out of the 76 
drugs assessed in the study, a total of 44 were deemed to bring an added benefit 
over the appropriate comparator by the G-BA, of which 34 had achieved price nego-
tiation as of end of May 2014. These ratings translated into an average innovation 
score of 1.77, and were subject to price cuts averaging 21.7%. ConClusions: Our 
analysis highlights that innovative medicines can be subject to significant price 
cuts in Germany. No correlation between the innovation score and subsequent 
price cuts could be derived, as many other factors, including the initial price dif-
ference between the new medicine and the comparator, enter into account as 
part of the price negotiations.
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objeCtives: If the cost-effectiveness and appropriate use of a drug in the 
Netherlands cannot yet be determined during the initial reimbursement assess-
ment (T= 0), this will be done at the re-evaluation 4 years later (T= 4) using RWD. 
Outcome research is an essential part of the re-evaluation of conditionally reim-
bursed drugs. The objective was to assess the reasons for accepting or rejecting 
outcome research results to confirm cost-effectiveness and appropriate use of 
a drug at T= 4. Methods: The website of Zorginstituut Nederland (ZiNL) was 
searched for re-evaluations of drugs published between January 2006 and May 
2014. ZiNL’s assessments of the outcome research were compared. Results: ZiNL 
published the outcome research results for four drugs. The outcome research 
results for agalsidase alfa & beta were accepted for demonstrating cost-effective-
ness and appropriate use in Fabry’s disease. The T= 4 results for omalizumab for 
